Skip to the main content.

Cell and Gene Therapy Series. Part 7 - Manufacturing Paradigms part II

Cell and Gene Blog Series: Part 7 - Future ATMP Manufacturing Paradigms

We wrap up this Cell and Gene series with a final blog - 7. Follow the link to continue learning about the future of ATMPs' manufacturing paradigm.

Inside 3P innovation’s Latest DPI Blister Filling and Sealing Platform

Inside 3P innovation’s Latest DPI Blister Filling and Sealing Platform

In this interview, Carl Jones, Projects Director at 3P innovation, discusses the company’s latest advancements in blister filling and sealing...

Read More
From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future

From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future

From Disruption to Reinvention: The Story of API-in-Capsule Technology and Its Future This article traces the evolution of API-in-capsule (AIC)...

Read More
What does Annex 1 mean for the cell & gene industry? Insights from 3P innovation.

What does Annex 1 mean for the cell & gene industry? Insights from 3P innovation.

The revision of EU GMP Annex 1 has redefined expectations for sterile manufacturing across the life sciences sector and nowhere is this felt more...

Read More